Tom Mikkelsen

Studying the heterogeneity of brain tumors using medium throughput LOH analysis.

Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.

Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas.

Angiogenesis in glioma: molecular mechanisms and roadblocks to translation.

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis.

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

Developing a brain tumor center.

Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.

Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles.

SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion.

Angiogenesis and apoptosis in glioma: two arenas for promising new therapies.

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.

A quantitative model of tumor-induced angiogenesis in the nude mouse.

AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma.

Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.

Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).

The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.

High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.

A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.

Proteomic comparison of oligodendrogliomas with and without 1pLOH.

2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions.

Cerebellar tumors in pediatric patients: can they be differentiated using diffusion-weighted imaging?

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.

Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells.

Altered adenosine-to-inosine RNA editing in human cancer.

First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis.

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.

FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway.

GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis.

Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells.

Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration.

Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival.

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.

Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care.

The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.

Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.

The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.

Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

An integrative approach for in silico glioma research.

Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.

Targeting integrins in malignant glioma.

Predicting survival in glioblastomas using diffusion tensor imaging metrics.

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

Recurrent high-grade glioma: a diagnostic and therapeutic challenge.

Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas.

Cilengitide induces autophagy-mediated cell death in glioma cells.

Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

Model selection for DCE-T1 studies in glioblastoma.

Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.

Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Integrated morphologic analysis for the identification and characterization of disease subtypes.

A prognostic gene expression signature in infratentorial ependymoma.

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

Phase I study of terameprocol in patients with recurrent high-grade glioma.

Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

Segmentation of corpus callosum using diffusion tensor imaging: validation in patients with glioblastoma.

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma.

A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma.

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Phase I study of GRN1005 in recurrent malignant glioma.

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.

MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor.

MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.

Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.

Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.

Prognostic vascular imaging biomarkers in high-grade gliomas: tumor permeability as an adjunct to blood volume estimates.

The Corpus Callosum Wallerian Degeneration in the Unilateral Brain Tumors: Evaluation with Diffusion Tensor Imaging (DTI).

Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal.

MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.

Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.

The integrated landscape of driver genomic alterations in glioblastoma.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.

Subcurative radiation significantly increases proliferation, invasion, and migration of primary GBM in vivo.

The somatic genomic landscape of glioblastoma.

Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme.

Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates.

Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.

Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.